Sun Pharmaceutical Industries Limited has initiated a postal ballot to secure shareholder approval for its new Employee Stock Option Plan 2026 (ESOP 2026) and significant enhancements to its borrowing and investment limits. These approvals are critical to facilitating the proposed acquisition of Organon & Co., a strategic move aimed at diversifying the company's global pharmaceutical portfolio.

ESOP 2026 framework and dilution impact

The company proposes adopting the ESOP 2026, which will be implemented through an irrevocable employee welfare trust. This plan allows for the grant of up to 12,000,000 options, each conferring the right to acquire one existing fully paid-up equity share. Crucially, the plan utilizes shares acquired from the secondary market, ensuring no fresh equity issuance and thus preventing dilution of existing shareholders' holdings. The exercise price is set at ₹1 per option, aligning with the face value, and vesting is performance-linked, typically over a five-year period with three equal annual instalments.

Financing limits for Organon acquisition

To support the proposed acquisition of Organon, Sun Pharma seeks to enhance its financial authorities under the Companies Act, 2013. The current borrowing limit stands at ₹500 billion, approved in 2014. The proposal seeks to increase this cap to ₹700 billion. Additionally, the limit for loans, guarantees, securities, and investments under Section 186 is proposed to rise from ₹500 billion to ₹800 billion. These enhanced limits are intended to provide the necessary headroom for acquisition financing, refinancing, and integration costs.

Security creation and regulatory compliance

The ballot also includes a request to create security interests, including mortgages and charges, up to ₹700 billion in favor of lenders. A specific resolution seeks approval under Regulation 24(5) of the SEBI Listing Regulations to pledge shares of Organon and its subsidiaries. This encumbrance is required to secure financing facilities aggregating up to $12 billion. The company notes that while Organon may become a material subsidiary, this approval is sought as a matter of governance best practice to facilitate the financing structure without requiring separate approvals during potential enforcement events.

What the Numbers Show

The data reveals a substantial expansion in Sun Pharma's financial capacity relative to its current utilization. As of June 30, 2026, the company had utilized only ₹134.3 billion of its existing ₹500 billion borrowing limit, representing approximately 27% usage. The proposed increase to ₹700 billion provides a significant buffer, suggesting the acquisition financing requires substantial debt capacity beyond current headroom. Furthermore, the decision to implement ESOPs via secondary market purchases rather than fresh issues indicates a strategic preference for protecting existing shareholder value while still offering competitive long-term incentives tied to performance metrics like Net Sales and Earnings Before Tax.

Sun Pharmaceutical Industries Limited announced that new long-term data for LEQSELVI (deuruxolitinib) demonstrated sustained efficacy and safety in adults with severe alopecia areata. The findings were presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026, highlighting durable hair regrowth over a two-year period.

The featured oral presentation reported results from an open-label extension study evaluating treatment up to two years. The safety profile remained generally consistent with previous clinical experience. Most treatment-emergent adverse events were mild or moderate, and discontinuations due to adverse events were uncommon. No deaths, thrombosis, or major adverse cardiovascular events were reported among patients receiving the FDA-approved dose of 8 mg twice-daily.

Long-term efficacy outcomes

Analyses presented in a poster indicated durable scalp hair regrowth through Week 108 in patients receiving LEQSELVI in the European open-label extension. Among baseline responders who maintained their response at Week 52 and continued in the study, 93.9% maintained that response at Week 108. Additionally, 76.6% of baseline nonresponders achieved a response by Week 52. Of those who achieved this response and continued, 96.8% maintained it at Week 108.

Clinical significance and portfolio context

Arash Mostaghimi, Vice Chair of Clinical Trials and Innovation at Brigham and Women’s Hospital, noted that severe alopecia areata is a chronic autoimmune disease where long-term treatment considerations are critical. He stated that the data reinforce the growing body of evidence supporting LEQSELVI as a long-term treatment option. Ahmad Naim, Senior Vice President and North America Chief Medical Officer at Sun Pharma, emphasized that the data expand understanding beyond initial treatment response to include long-term tolerability and durability of benefit.

The company presented seven presentations on LEQSELVI at the congress, which was part of 22 total presentations from Sun Pharma across its dermatology and immunology portfolio. Pooled post hoc analyses of THRIVE-AA1 and THRIVE-AA2 trials showed consistent efficacy across clinically relevant subgroups, including patients with eyebrow, eyelash, or nail involvement.

What the numbers show

The data reveals a strong conversion rate from non-response to response within the first year, with 76.6% of initial nonresponders achieving clinical success by Week 52. This high conversion rate suggests that a significant portion of the patient population may derive benefit even if they do not respond immediately. Furthermore, the high maintenance rates (93.9% and 96.8%) among responders indicate that once clinical benefit is established, it is highly likely to persist over the two-year observation period, addressing a key concern in chronic autoimmune management.